BMY 28100, a new oral cephalosporin with a (Z)-propenyl side chain at the 3 position and a phydroxyphenylglycyl substituent at the 7 position, was evaluated in comparison with cefaclor and cephalexin and, when appropriate, ampicillin and vancomycin. In vitro, BMY 28100 was more active than the reference cephalosporins against streptococci, Staphylococcus aureus, Staphylococcus epidermidis, Listeria nionocytogenes, Haemophilus influenzae, Propionibacterium acnes, Clostridiunm perfrigens, and Clostridium difficile. BMY 28100 was comfparable to cefaclor and more active than eephalexin against Staphylococcus saprophyticus and ampicillin-susceptible strains of Branhamella cattarhalis; but against ampicillin-resistant strains of B. cattarhalis, BMY 28100 was comparable to cephalexin and more active than cefaclor. Against Neisseria gonorrhoeae, BMY 28100 was comparable to cephalexin, but less active than cefaclor. Members of the family Enterobacteriaceae overall were equally susceptible to BMY 28100 and cefaclor but were less susceptible to cephalexin. In human serum, BMY 28100 was 45% protein bound. After an oral dose to mice, 82% of the drug was recovered in urine. The oral therapeutic efficacy of BMY 28100 in systemically infected mice reflected its activity in vitro.
Whereas parenteral cephalosporins have been prepared with an array of side chains at the 3 and 7 positions, structural requirements for good gastrointestinal absorption have limited the choice of side chains for oral cephalosporins. The number of distinct substituents at the 3 position on oral cephalosporins currently in clinical use is small, and all substituents at the 7 position are of a single design: a native or modified phenyglycyl radical. Recent attempts to deviate from this pattern have yielded compounds with a broader spectrum of activity against gram-negative organisms but reduced gastrointestinal absorption and little antistaphylococcal activity (4, 9, 13 Zak, and R. Scartazzini, Program Abstr. 25th Intersci. Conf. Antimicrob. Agents Chemother., abstr. no. 595, 1985) .
BMY 28100 is a new oral cephalosporin of conventional design. It has a (Z)-propenyl side chain at the 3 position and ap-hydroxyphenylglycyl substituent at position 7 ( Fig. 1) . In this report we compare the biological and physicochemical properties of BMY 28100 with those of the two most widely used oral cephalosporins, cephalexin and cefaclor. When appropriate, ampicillin and vancomycin were also included as reference compounds.
(This study was presented in part at the 14th International Congress of Chemotherapy, Kyoto, Japan [F. Leitner by the slope of the line. The area under the drug concentration-time curve was obtained by successive trapezoidal approximation from time zero to 2.5 h.
Urine was collected in three fractions (0 to 3, 3 to 6, and 6 to 24 h), and drug recovery was determined as described previously (10) .
Therapeutic efficacy in systemically infected mice. Male Swiss-Webster mice (weight, 20 ± 2 g) were challenged intraperitoneally with 0.5 ml of a bacterial suspension containing a sufficient number of organisms to kill untreated controls within 72 h. Streptococci were suspended in brain heart infusion broth (Difco), penicillinase-producing staphylococci were suspended in broth containing 2% hog gastric mucin (American Laboratories, Inc., Omaha, Nebr.), and the other organisms were suspended in broth containing 4% mucin. Animals were treated by gavage. Experimental conditions were as described previously (11) . The SpearmanKarber method (7) was used to calculate 95% confidence limits.
RESULTS
Antimicrobial spectrum. BMY 28100 was 2 to 8 times more active than cefaclor and 8 to 32 times more active than cephalexin against streptococci other than enterococci (Table 1). Streptococcus faecalis was inhibited by 8 to 16 ,ug of BMY 28100 per ml, and Streptococcus faecium was inhibited by 8 to 32 pug of BMY 28100 per ml. Cefaclor was 2 to 4 times less active and cephalexin was more than 10 times less active than BMY 28100. All penicillinase-producing strains of Staphylococcus aureus were inhibited by 4 ,ug or less of BMY 28100 per ml compared with 32 ,ug/ml for cefaclor and cephalexin. Against Staphylococcus aureus lacking penicillinase and Staphylococcus epidermidis, BMY 28100 was two-to fourfold more active than cefaclor and about eightfold more active than cephalexin; against Staphylococcus saprophyticus, BMY 28100 was twofold more active than cefaclor and four to eight times more active than cephalexin. L. monocytogenes was susceptible to BMY 28100, moderately susceptible to cefaclor, and resistant to cephalexin.
Against H. influenzae, with half of the strains being ,-lactamase producers, BMY 28100 had a twofold advantage over cefaclor and cephalexin. Although all three compounds were approximately equally active against B. catarrhalis, BMY 28100 and cephalexin tended to be more active than cefaclor or ampicillin against those strains with higher MICs for ampicillin. Twenty-five strains of N. gonorrhoeae were ampicillin susceptible and eight were ampicillin resistant. MICs of the cephalosporins for the ampicillin-resistant strains clustered near the upper end of the MIC range of the ampicillin-susceptible strains. BMY 28100 activity was comparable to that of cephalexin but lower than that of cefaclor.
Against Proteus mirabilis, BMY 28100 and cefaclor had similar ranges of growth-inhibitory activities but BMY 28100 was two-to fourfold more active than cefaclor. The two cephalosporins were 16-to 32-fold more active than cephalexin against 80% of the strains but had a lesser or no advantage against the remaining strains. Against Escherichia coli, the MIC50 (MIC for 50% of strains tested) of BMY 28100 was fourfold lower than that of cefaclor or cephalexin; the MIC90s (MICs for 90% of strains tested) of all three were >125 ,ug/ml. Against Shigella spp., Salmonella spp., and Citrobacter diversus, BMY 28100 activity overall was comparable to that of cefaclor, and for the majority of strains BMY 28100 was more active than cephalexin. About onequarter of the strains, however, were either more susceptible to cephalexin or similarly susceptible to BMY 28100 and cephalexin. Against Klebsiella pneumoniae and Klebsiella oxytoca, BMY 28100 and cefaclor were comparably active. The more susceptible strains were inhibited to a greater extent by BMY 28100; the more resistant strains were inhibited to a greater extent by cephalexin.
Propionibacterium (lacking 1-lactamase) and E. coli (13-lactamase producer), the maximum cidal rate of the cephalosporins corresponded to a t1llo of approximately 1.25 h. The lowest cephalosporin concentrations that prevented regrowth of H. influenzae between 8 and 24 h were as follows: BMY 28100, 1 ,ug/ml; cefaclor, 2 ,ug/ml; cephalexin, 4 ,ug/ml. The corresponding values for E. coli were 4, 8, and 16 ,ug/ml. Binding to serum proteins. In 95% human serum, BMY 28100 was 45% protein bound and cephalexin was 17% protein bound. Under similar experimental conditions cefaclor was 47% protein bound (14) .
Stability in solution at 37°C. BMY 28100, cefaclor, and cephalexin had a half-life of more than 24 h in citrate buffer (pH 2.0). In phosphate buffer (pH 7.4) and in 95% human serum, the half-life of BMY 28100, 4.8 and 5.5 h, respectively, was twice that of cefaclor (2.3 and 2.7 h, respectively). In either medium the activity of cephalexin declined with a half-life of >24 h. were comparable to those of cephalexin and more favorable than those of cefaclor (Table 2 ). About 95% of the dose recovered in urine was excreted during the first 3 h after administration.
Therapeutic efficacy in systemically infected mice. BMY 28100 was more effective than the two reference compounds against infections caused by streptococci and penicillinaseproducing Staphylococcus aureus strains (Table 3) . A penicillinase-negative strain of Staphylococcus aureus was equally susceptible to treatment by any one of the cephalosporins. The inefficacy of cefaclor in treating staphylococcal infections caused by penicillinase-producing strains no doubt reflects its relative lability to the enzyme. Against infections with gram-negative organisms H. influenzae, Proteus mirabilis, E. coli, and K. pneumoniae, BMY 28100 was comparable to cefaclor and more effective than cephalexin. DISCUSSION BMY 28100 is a new oral cephalosporin of traditional structural design. In vitro the compound was more active than cefaclor and cephalexin against streptococci, including enterococci, Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus saprophyticus, L. monocytogenes, and H. influenzae. The larger differential in activity between BMY 28100 and cefaclor against penicillinaseproducing Staphylococcus aureus isolates compared with that of nonproducers suggest that BMY 28100 is hydrolyzed more slowly than cefaclor. The relative rate of hydrolysis by purified enzyme is 10-fold less for BMY 28100 compared with that for cefaclor (unpublished results). BMY 28100 activity was comparable to that of cefaclor and higher than that of cephalexin against ampicilin-susceptible strains of B. catarrhalis, but against ampicillin-resistant strains of this organism BMY 28100 activity was comparable to that of cephalexin and higher than that of cefaclor. Against N. gonorrhoeae, BMY 28100 activity was comparable to that of cephalexin but lower than that of cefaclor. Members of the family Enterobacteriaceae overall were equally susceptible to BMY 28100 and cefaclor and less susceptible to cephalexin. However, the MIC50 of BMY 28100 for E. coli was fourfold lower than for both cefaclor and cephalexin, suggesting a small advantage for this species alone. With many species, susceptibility to BMY 28100 and cefaclor was bimodal, and, thus, cephalexin often had an advantage against the more resistant strains, particularly at the higher inoculum.
BMY 28100 displayed unexpectedly good activity against C. difficile, which is the causative agent of antibioticassociated pseudomembranous colitis. The disease is thought to be caused by an imbalance in the colonic flora, which is generated by the administration of antibiotic and which permits proliferation of toxigenic C. difficile isolates either during or after cessation of treatment. Parenteral and oral cephalosporins are among the antibiotics that have been implicated in the disease (1, 3) . There are reports of cases in which an antibiotic has been effective in vitro against the offending strain (5). Hence, the clinical relevance of activity in vitro is not clear. An investigation of the relative liabilities significantly longer than that of cephalexin (P < 0.001). AUC02.5, Area under the concentration-time curve from 0 to 2.5 h after drug administration.
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LEITNER ET AL. The oral therapeutic efficacy of BMY 28100 in systemically infected mice was congruent with its activity in vitro. BMY 28100 is currently in clinical trial.
